V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210000349 | 210013901 | 1.65 | 83 | Neo-adjuvant (N) | null | 2020-08-11 | Pertuzumab (Loading) | 02 | N | PERTUZUMAB | 100771838 |
| 210001109 | 210013905 | 1.61 | 102.85 | Neo-adjuvant (N) | null | 2019-01-10 | PERTUZUMAB + TRASTUZUMAB | 02 | N | PERTUZUMAB + TRASTUZUMAB | 100904517 |
| 210001120 | 210013906 | 1.76 | 66 | Adjuvant (A) | null | 2021-12-18 | Letrozole + Palbociclib | 02 | null | CARBOPLATIN + PACLITAXEL | 100823922 |
| 210001184 | 210013908 | null | 76.9 | null | 2019-08-23 | 2019-12-09 | Capecitabine | 02 | null | CAPECITABINE | 100896768 |
| 210001616 | 210013909 | 1.57 | 103.05 | null | 2021-03-31 | 2021-04-01 | GemCarbo Days 1+8 | 02 | null | CARBOPLATIN + GEMCITABINE | 101284861 |
| 210001833 | 210013910 | 1.74 | 87.1 | Adjuvant (A) | null | 2022-03-23 | Capecitabine | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101799390 |
| 210001876 | 210013911 | 1.52 | 67 | Neo-adjuvant (N) | 2020-12-29 | 2021-01-19 | PERTUZUMAB + TRASTUZUMAB | 02 | N | PERTUZUMAB + TRASTUZUMAB | 100936518 |
| 210002127 | 210013915 | 1.71 | 91.5 | null | 2021-06-22 | 2021-07-09 | null | 02 | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 100657281 |
| 210002144 | 210013916 | 1.7 | 98.9 | null | 2022-02-15 | 2022-02-26 | VINORELBINE | N | null | VINORELBINE | 100163344 |
| 210002362 | 210013917 | 1.58 | 60 | Adjuvant (A) | 2021-05-20 | 2021-05-20 | PERTUZUMAB + TRASTUZUMAB | 02 | N | PERTUZUMAB + TRASTUZUMAB | 100908757 |
| 210002443 | 210013918 | 1.76 | 68.5 | null | 2021-05-09 | 2021-05-11 | PERTUZUMAB + TRASTUZUMAB | 02 | null | PERTUZUMAB + TRASTUZUMAB | 101261577 |
| 210003252 | 210013920 | 1.59 | 128.6 | null | null | 2022-04-13 | CARBOPLATIN | 02 | null | CARBOPLATIN | 101129757 |
| 210003324 | 210013921 | null | null | null | 2022-01-29 | 2022-02-17 | null | 02 | null | PACLITAXEL + TRASTUZUMAB | 100837867 |
| 210003466 | 210013922 | 1.74 | 94 | Palliative (P) | null | 2021-12-03 | null | 02 | N | EVEROLIMUS | 100042368 |
| 210003473 | 210013923 | 1.66 | 53 | Curative (C) | 2021-06-13 | 2021-06-20 | null | 02 | N | LIPOSOMAL DOXORUBICIN | 100851270 |
| 210003476 | 210013924 | 1.46 | 80.1 | Adjuvant (A) | null | 2020-03-24 | Paclitaxel+Trastuzumab wkly Maint | 02 | N | PACLITAXEL + TRASTUZUMAB | 100010778 |
| 210003548 | 210013925 | 1.7 | 52 | Palliative (P) | 2019-11-26 | 2019-12-04 | DOCETAXEL + TRASTUZUMAB | null | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100525179 |
| 210003809 | 210013956 | 1.71 | null | Palliative (P) | null | 2021-06-26 | Docetaxel 100mg/m2 (21 day) | 02 | null | DOCETAXEL | 101688181 |
| 210003814 | 210013957 | 1.48 | 64.5 | Adjuvant (A) | null | 2018-06-15 | EC | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100731635 |
| 210003824 | 210013958 | null | null | null | null | 2020-02-07 | Docetaxel | 2 | null | DOCETAXEL | 100036411 |
| 210003826 | 210013959 | 0 | 60.55 | Adjuvant (A) | null | 2020-10-28 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101339951 |
| 210003834 | 210013960 | null | null | null | 2022-01-01 | 2022-03-18 | Docetaxel | 02 | null | DOCETAXEL | 100149178 |
| 210003845 | 210013961 | 1.47 | 76 | Adjuvant (A) | null | 2022-05-11 | Docetaxel | 02 | N | DOCETAXEL | 100474186 |
| 210003852 | 210013962 | 1.72 | 86.6 | Neo-adjuvant (N) | null | 2020-08-21 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100647356 |
| 210003862 | 210013964 | null | null | Curative (C) | 2020-11-07 | 2021-01-25 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 100376955 |
| 210003870 | 210013966 | 1.75 | 77.1 | Palliative (P) | 2021-09-23 | 2021-10-11 | EC | N | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101050368 |
| 210000062 | 210013969 | 1.55 | 65.7 | Adjuvant (A) | 2018-09-26 | 2020-05-18 | Paclitaxel albumin (Abraxane) 21day | null | N | NAB-PACLITAXEL | 100225173 |
| 210000349 | 210013971 | null | null | null | 2019-02-18 | 2020-09-08 | Neratinib | 02 | null | NERATINIB | 100771838 |
| 210001086 | 210013973 | null | 70.3 | null | null | 2022-03-21 | Capecitabine | null | null | CAPECITABINE | 101663547 |
| 210001120 | 210013975 | 1.47 | 75.2 | null | 2022-02-26 | 2022-03-13 | Capecitabine | 02 | null | CAPECITABINE | 100823922 |
| 210001126 | 210013976 | 1.5 | 0 | Palliative (P) | 2020-09-19 | 2021-01-09 | Capecitabine | 02 | N | CAPECITABINE | 101674658 |
| 210001616 | 210013978 | 1.62 | 80.1 | Adjuvant (A) | 2022-03-10 | 2022-03-10 | Epirubicin | 02 | N | CARBOPLATIN + PACLITAXEL | 101284861 |
| 210001833 | 210013979 | 1.62 | 71 | Neo-adjuvant (N) | 2022-04-09 | 2022-04-24 | EC | 02 | N | EC | 101799390 |
| 210002038 | 210013981 | 1.64 | 89.1 | Palliative (P) | null | 2022-03-28 | Palbociclib | null | N | PACLITAXEL + TRASTUZUMAB | 101316970 |
| 210002127 | 210013983 | 1.64 | 87.8 | null | null | 2021-08-13 | null | 02 | null | CARBOPLATIN + PACLITAXEL | 100657281 |
| 210003226 | 210013986 | null | null | null | null | 2020-12-11 | Carboplatin AUC 2 - 5 | 02 | null | CARBOPLATIN | 100456723 |
| 210003252 | 210013987 | 1.57 | 124.4 | null | 2021-09-06 | 2022-05-14 | null | 02 | null | LETROZOLE + PALBOCICLIB | 101129757 |
| 210003324 | 210013988 | 1.44 | 71.5 | Palliative (P) | 2022-01-19 | 2022-02-17 | null | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100837867 |
| 210003466 | 210013989 | 1.64 | 68.9 | null | 2021-12-22 | 2022-01-19 | Bevacizumab + CARBOPLATIN + PACLITAXEL | null | null | SACITUZUMAB GOVITECAN | 100042368 |
| 210003725 | 210013993 | 1.53 | 68 | null | null | 2022-01-10 | Capecitabine | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100388097 |
| 210003852 | 210014015 | 1.56 | 77.3 | null | null | 2020-11-06 | PACLITAXEL | null | null | PACLITAXEL | 100647356 |
| 210003858 | 210014016 | 1.47 | null | Palliative (P) | 2019-11-18 | 2019-11-30 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 101594501 |
| 210003870 | 210014018 | 1.49 | 50.4 | Palliative (P) | null | 2021-11-18 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | N | PACLITAXEL | 101050368 |
| 210000062 | 210014020 | 1.68 | 63.1 | null | 2020-03-01 | 2020-05-18 | Trastuzumab Subcutaneous | null | null | TRASTUZUMAB | 100225173 |
| 210001184 | 210014025 | 1.77 | 65 | Neo-adjuvant (N) | 2020-08-27 | 2022-02-13 | Capecitabine | null | N | CAPECITABINE | 100896768 |
| 210001616 | 210014026 | 1.65 | 84 | null | null | 2022-05-27 | Capecitabine | 02 | null | CAPECITABINE | 101284861 |
| 210001994 | 210014028 | 1.7 | null | Palliative (P) | null | 2020-03-03 | Everolimus 10mg | null | N | CARBOPLATIN + DOCETAXEL | 100155303 |
| 210002107 | 210014029 | 1.55 | 74.4 | null | 2019-01-24 | 2020-08-30 | null | 02 | null | TRIAL UNSPECIFIED | 101536240 |
| 210003324 | 210014032 | null | null | Neo-adjuvant (N) | 2021-12-02 | 2022-02-17 | Atezolizumab | null | null | ROSCO TRIAL | 100837867 |
| 210003466 | 210014033 | null | null | null | null | 2022-02-28 | FEC 100 | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100042368 |